B7-H3 chimeric antigen receptor-modified T cell shows potential for targeted treatment of acute myeloid leukaemia

BACKGROUND AND AIMS: Chimeric antigen receptor (CAR)-T cell therapy is a novel type of immunotherapy. However, the use of CAR-T cells to treat acute myeloid leukaemia (AML) has limitations. B7-H3 is expressed in several malignancies, including some types of AML cells. However, its expression in norm...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Shuangshuang, Wang, Tian, You, Fengtao, Zhang, Tingting, Li, Yafen, Ji, Cheng, Han, Zhichao, Sheng, Binjie, Zhai, Xiaochen, An, Gangli, Meng, Huimin, Yang, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026503/
https://www.ncbi.nlm.nih.gov/pubmed/36941687
http://dx.doi.org/10.1186/s40001-023-01049-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026503/
https://www.ncbi.nlm.nih.gov/pubmed/36941687
http://dx.doi.org/10.1186/s40001-023-01049-y

Ejemplares similares